The conclusion of the pharmaceutical package by the European Union is a significant moment in shaping the future of one of Europe’s most strategically important sectors, supporting the health and economic security of Europe and impacting patient care for decades.

While the package contains signals that the EU recognises the importance of the legislation as a key driver of competitiveness for the innovative pharmaceutical sector in Europe, it is not strong enough to move the needle on European competitiveness – a key objective of this Commission.

If Europe truly wants to be competitive it needs to increase investment in innovative medicines, strengthen rather than weaken IP and make the process of getting new medicines to patients faster and more connected.